LUXEMBOURG (July 22, 2014 ) — ConvaTec, a privately-held medical products and technologies company, today announced that Nigel Clerkin has been appointed chief financial officer of the company, effective July 22, 2014.
Mr. Clerkin was previously executive vice president and chief financial officer of Elan Corporation, a Dublin-based biotechnology company. Mr. Clerkin was part of a senior team that helped build significant shareholder value at Elan, culminating in its sale to Perrigo, a pharmaceutical manufacturer, in December 2013.
“I am very pleased to welcome Nigel to ConvaTec,” said Ken Berger, CEO of ConvaTec. “His track record in creating value at a major public company will be a great asset for us as we grow and evolve as a company.”
“ConvaTec has outstanding products, a great reputation and a proven business platform that is primed to take advantage of emerging healthcare trends,” said Mr. Clerkin. “I am delighted to join ConvaTec at a very exciting time for the company.”
Mr. Clerkin joined Elan in 1998 and held a series of roles in strategic planning and finance prior to being named CFO in 2011. Earlier, Mr. Clerkin was an auditor with KPMG. He holds bachelor’s and master’s degrees in accounting from Queens University, Belfast, and is a fellow of Chartered Accountants Ireland.
Mr. Clerkin succeeds John Cannon, who will remain at ConvaTec as senior vice president, financial operations.
ConvaTec is a global medical products and technologies company, with leading market positions in wound therapeutics, ostomy care, continence and critical care, and infusion devices. Our products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. ConvaTec has over 8,000 employees, with 11 manufacturing sites in 8 countries, and we do business in more than 100 countries. We are owned by Nordic Capital and Avista Capital Partners.